Enteropathy-Associated T-Cell Lymphoma
Associated Genetic Biomarkers
NCI Definition: An uncommon mature T-cell lymphoma of intraepithelial lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum. Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is seen with increased frequency in regions with a high prevalence of celiac disease. 
There are 19 clinical trials for enteropathy-associated T-cell lymphoma, of which 18 are open and 1 is completed or closed. Of the trials that contain enteropathy-associated T-cell lymphoma as an inclusion criterion, 2 are early phase 1 (2 open), 3 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), 10 are phase 2 (9 open), and 1 is no phase specified (1 open).
TNFRSF8, CD5, and CD7 are the most frequent gene inclusion criteria for enteropathy-associated T-cell lymphoma clinical trials .
Brentuximab vedotin, cyclophosphamide, and doxorubicin are the most common interventions in enteropathy-associated T-cell lymphoma clinical trials.
Significant Genes in Enteropathy-Associated T-Cell Lymphoma
ALK is an inclusion eligibility criterion in 2 clinical trials for enteropathy-associated T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and enteropathy-associated T-cell lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.